Yan Shu

Dr. Yan Shu is a Professor in the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy. He holds both an MD and a PhD in Pharmaceutical Sciences & Pharmacogenomics from the University of California, San Francisco, and previously trained at Hunan Medical University in China. His research is centered on the genetic and epigenetic mechanisms of drug response, with a strong emphasis on membrane transporters, metabolic diseases, and clinical pharmacology.

Dr. Shu's research spans several key areas: (1) the role of genetic variations in drug-induced metabolic disorders and diabetes, particularly through the TCF7L2 gene and Wnt signaling; (2) regulatory mechanisms of drug transporters such as OCT1 and MATEs; and (3) drug-drug interactions mediated by transporter systems. His lab utilizes molecular and cellular biology, mouse models, metabolomics, and clinical studies to translate findings into clinical outcomes.

The recent publications from Dr. Shu’s group reflect a strong trend in pharmacogenomics, transporter biology, and drug toxicity. His work frequently investigates how genetic polymorphisms and regulatory proteins influence the pharmacokinetics and safety of drugs like metformin, cisplatin, and telmisartan. There is a clear focus on transporter-mediated drug interactions and their clinical implications, especially in the kidney and liver.

Dr. Shu has not been explicitly mentioned as receiving scientific awards in the provided text.

He actively mentors postdoctoral fellows and students, including Qing Li, Wei Zhang, and Dong Guo, and has previously advised several PhD and MSc graduates. There is no mention of specific grants, but his collaborations with the FDA suggest active funding. His lab, the Shu Lab, operates within the University of Maryland School of Pharmacy and uses advanced methodologies including genetically modified mouse models, bioanalysis, and clinical trial data.

The Shu Lab is equipped with expertise in pharmacokinetics, pharmacodynamics, metabolomics, and genetic modeling, and continues to investigate novel regulatory mechanisms like IRIP in drug transport. The team is actively working on improving cancer therapy and reducing drug-induced toxicities through a better understanding of transporter function.